DiaSorin S.p.A. develops, produces, and commercializes diagnostic tests in various clinical areas for hospital and private testing laboratories in the market of immunodiagnostics and molecular diagnostics. It offers immunodiagnostics products in the areas of infectious diseases; bone and mineral metabolism; endocrinology, including diabetes, thyroid function, fertility, growth, adrenal function, and gastroenterology; hypertension; oncology; stool diagnostics; autoimmunity; and cardiac and brain damages. The company's immunodiagnostics systems include LIAISON XL, an automated chemiluminescence analyzer; LIAISON analyzer; EVOlyzer 2-150/8 with disposable tips to automate microplate based assays; and ETI Max 3000, an automated microtiter plate analyzer. It also offers molecular diagnostic products LIAISON MDX a thermocycler; and LIAISON IAM, an instrument for amplification of nucleic acids, as well as kits, PCR master mixes, primer pairs, and molecular controls for monitoring oncology and infectious diseases. The company sells its products directly, as well as through an international network of independent distributors in Europe, Africa, North Americam Central America, South America, and the Asia Pacific. DiaSorin S.p.A. was founded in 1968 and is headquartered in Saluggia, Italy.
Industry, Sector and Symbol
Industry N/A
Sub-IndustryN/A
SectorN/A
CIKN/A
WebN/A
PhoneN/A
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees1,928
Next Earnings Date4/27/2020 (Estimated)
OptionableNot Optionable
DiaSorin (OTCMKTS:DSRLF) Frequently Asked Questions
What is DiaSorin's stock symbol?
DiaSorin trades on the OTCMKTS under the ticker symbol "DSRLF."
When is DiaSorin's next earnings date?
Has DiaSorin been receiving favorable news coverage?
News headlines about DSRLF stock have trended somewhat positive this week, according to InfoTrie Sentiment. The research group identifies positive and negative news coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. DiaSorin earned a media sentiment score of 2.0 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the company's share price in the next several days. View News Stories for DiaSorin.
What other stocks do shareholders of DiaSorin own?
Who are DiaSorin's key executives?
DiaSorin's management team includes the folowing people:
- Mr. Carlo Rosa, CEO, GM & Exec. Director (Age 53)
- Dr. Chen Menachem Even, Chief Commercial Officer & Exec. Director (Age 56)
- Mr. Piergiorgio Pedron, Corp. Accounting Documents Officer, CFO & Sr. Corp. VP (Age 48)
- Mr. Riccardo Fava, Sr. Director of Investor Relations & Corp. Communication
- Mr. Marco Minolfo, Mang. of the Corp. Legal Affairs Department
How do I buy shares of DiaSorin?
Shares of DSRLF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is DiaSorin's stock price today?
One share of DSRLF stock can currently be purchased for approximately $128.00.
MarketBeat Community Rating for DiaSorin (OTCMKTS DSRLF)
MarketBeat's community ratings are surveys of what our community members think about DiaSorin and other stocks. Vote "Outperform" if you believe DSRLF will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DSRLF will underperform the S&P 500 over the long term. You may vote once every thirty days.
